To facilitate global research about drugs or vaccines for COVID-19, Creative Biolabs has launched a series of antiviral drug discovery services for SARS-CoV-2, including High-Throughput Screening and Antiviral Agents Discovery.
As COVID-19 is still spreading around many countries around the world, global scientists are expediting the research on specific drugs or vaccines. As a world-leading service provider in the field of life science, Creative Biolabs provides a complete set of technical services and scientific support to bring valuable and potent novel drug candidates for clients.
Creative Biolabs introduces its SARS-CoV-2 antiviral drug discovery services covering inhibitors discovery, neutralizing antibody development, antiviral peptide discovery, broad-spectrum antiviral drugs discovery, High-Throughput Screening of novel drug candidates, etc. The multi-CoV panel assay is available to screen drug candidates, assess the specificity of antivirals and mAbs, and to help identify and evaluate items with broad-spectrum antivirals activities.
- Antiviral Agents
Creative Biolabs provides different kinds of antiviral agents. For example, various inhibitors can play an antiviral role, such as nucleoside analogue inhibitors, viral protease inhibitors, host cell protease inhibitors, Abelson kinase inhibitors, RNA synthesis inhibitors and neuraminidase inhibitors. Neutralizing antibodies used for the prophylaxis and early treatment of emerging viral infections, and antiviral peptide to interfere with refolding and prevent infection are also available at Creative Biolabs. Broad-spectrum antiviral drugs are mainly broad-spectrum antiviral drugs such as interferon α and β, and anti-inflammatory drugs such as hormones and other molecules.
- High-Throughput Screening (HTS)
HTS, a flexible and reliable automated process used in drug discovery, can rapidly identify hits from compound libraries, such as active compounds, inhibitors, proteins, antibodies and peptides. HTS has shown great potential in broad-spectrum anti-CoV agents discovery. And HTS of large compounds libraries has already identified several effective antiviral agents against CoV infection.
Although HTS is an automated screening process, there are still many steps that need to be carefully monitored along the way. Each statistical parameter is valuable to the drug screening process. Based on thorough consideration of compounds library, suitable assays, robotic system and data analysis system, the SARS-CoV-2 HTS technology of Creative Biolabs can rapidly identify promising antiviral agents against SARS-CoV-2 infection from large libraries of approved drugs and pharmacologically active compounds, inhibitors, proteins, antibodies and peptides.
When the novel coronaviruses firstly broke out at the end of 2019, Creative Biolabs quickly organized relevant researchers, and set up a dedicated research team to carry out intensive analysis and research on the SARS-COV-2. Relying on the mature drug development and vaccine development technology and experience, Creative Biolabs provides global scientists with excellent CRO services regarding to drug discovery services, vaccine development services, preclinical research services, various in vivo and in vivo research models, and in vivo diagnostic immunoassay services.
Further information can be found on https://sars-cov-2.creative-biolabs.com.
About Creative Biolabs
Empowered by leading technology and over 15 years of experience in biomedical science, Creative Biolabs has successfully accomplished numerous challenging projects for customers in requirements with accumulated experience in drug discovery and vaccine development. Especially in the field of antiviral drugs and vaccines, Creative Biolabs provides drug discovery, vaccine design, preclinical evaluation of drugs and vaccines, and in vitro diagnostic services at the world-leading level.